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Abstract
It is very rare to find reports concerning a drug therapy successively treating 
chromosomal abnormalities. In this paper, we are reporting a successive use of 
nitisinone in treating a fatal and very rare autosomal disease called hereditary tyro-
sinemia type-1 [HT-1]. HT-1 is affecting about one person in 100,000 to 120,000 
births worldwide. It is due to a genetic defect in the enzyme fumarylacetoacetate 
hydroxylase (FAH), which is responsible for the final degradation of tyrosine. 
Accumulation of tyrosine metabolites is responsible for tissue damage such as 
liver, kidney, and neural tissues, finally causing the death of the newborn babies 
in their early months of life if not treated. Fumarylacetoacetate hydrolase gen has 
mapped on chromosome 15q23-15q25. Since 1992, the initiation of treating HT-1 
with nitisinone (NTBC) has become the medical therapy of choice in combination 
with diet. NTBC therapy has shown a direct correlation between age of initiation 
and subsequent clinical course. We are reporting three brothers treated safely and 
successively with NTBC in combination with diet. All of them are in very good 
conditions. The elder brother is on NTBC since 27 years ago.
Keywords: autosomal diseases, hepatocellular tyrosinemia, nitisinone, NTBC, 
hepatocellular carcinoma, newborn screening
1. Introduction
1.1 Tyrosine
Tyrosine (4-hydroxyphenylalanine) is a nonessential amino acid with a polar 
side group, 1 of the 22 amino acids that are used by cells to synthesize proteins. 
Tyrosine is also a precursor to neurotransmitters (catecholamines) and hormones 
(thyroxine and melatonin) [1–3]. In humans, tyrosine is obtained from two sources, 
dietary intake and hydroxylation of phenylalanine [4, 5]. Tyrosine degradation 
as shown in Figure 1 is catalyzed by a series of five enzymatic reactions that yield 
acetoacetate, which is ketogenic, and the Krebs cycle intermediate fumarate, which 
is glucogenic [4, 6, 7]. Although tyrosine degradation occurs mainly in the liver 
but to a lesser extent, it occurs in the proximal renal tubules [5, 8, 9]. Impaired 
catabolism of tyrosine is a feature of several acquired and genetic disorders. Four 
autosomal-recessive disorders result from deficiencies in specific enzymes in the 
tyrosine catabolic pathway: hereditary tyrosinemia (HT) types 1, 2, and 3, and 
alkaptonuria (AKU). These disorders result in elevated blood tyrosine levels except 
for AKU [4, 7, 9–11].
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2. Hereditary tyrosinemia type 1 (HT-1)
Synonyms: hepatorenal tyrosinemia (HRT), tyrosinemia type-1, hereditary 
infantile tyrosinemia, congenital tyrosinosis, and fumarylacetoacetate hydrolase 
(FAH) deficiency (FAHD), and is assigned OMIM 276700.
2.1 History
Inborn errors of metabolism (IEMs) are a group of diseases involving a genetic 
defect that alters a metabolic pathway and that presents during infancy.
The tyrosine degradation pathway contains five enzymes, four of which are 
associated with IEMs. The most severe metabolic disorder associated with this 
catabolic pathway is hereditary tyrosinemia type 1 (HT-1; OMIM 276700) [10].
In 1932, American biochemist Grace Medes, at the University of Minnesota 
Medical School in Minneapolis, first described “a new disorder of tyrosine metabo-
lism” and called it “tyrosinosis” after observing 4-hydroxyphenylpyruvate in the 
urine of a 49-year-old man with myasthenia gravis [12]. She proposed that the 
metabolic defect in this patient was a deficiency of 4-hydroxyphenylpyruvate 
dioxygenase.
In 1957, Japanese scientists, Kiyoshi Sakai and colleagues, published three 
reports describing the clinical, biochemical, and pathological findings of a 2-year-
old boy with hepatorenal tyrosinemia who was then thought to have an “atypical” 
case of tyrosinosis (“atypical” because it differed from the supposedly prototypical 
case reported by Medes) [13–16].
Then, between 1963 and 1965, Swedish pediatrician Rolf Zetterström and 
associates published the first detailed descriptions of hepatorenal tyrosinemia 
and its variants, a disorder then hypothesized to be caused by a defective 
4-hydroxyphenylpyruvate dioxygenase enzyme [17–20]. Furthermore, in 1964 
several pediatricians in Chicoutimi (Quebec-Canada) became aware of an 
increased incidence of infantile liver cirrhosis that was later recognized to be due 
to hereditary tyrosinemia type [21, 22]. Both the Scandinavian and Canadian 
groups suggested that the Japanese patients described earlier by Sakai and col-
leagues had the same disorder, that is, HT-1 [16]. Therefore, it has been consid-
ered that the first definite case report in the world of HT-1 was in Japan by Sakai 
and colleagues in 1957 [23].
2.2 Pathophysiology
Hereditary tyrosinemia type 1 is an inborn error of metabolism, inherited 
as an autosomal recessive disorder. The biochemical defect was shown to be 
Figure 1. 
The steps of tyrosine degradation.
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due to a genetic defect causing a deficiency (weak activity) or absence in 
the enzyme fumarylacetoacetate hydrolase (FAH), the enzyme catalyzing 
the final step of tyrosine catabolism pathway as shown in Figure 2 [24, 25]. 
Fumarylacetoacetate hydrolase gen has located on chromosome 15q23-
15q2515q23 and is composed of 14 exons [26]. This enzyme defect leads to 
subsequent accumulation of the amino acid tyrosine and its toxic metabolites 
such as succinylacetone, maleylacetoacetate, and Fumarylacetoacetate in the 
blood and tissues such as the liver, kidney, heart, and peripheral nerves, leading 
to dysfunction of these organs [24, 27–30]. The patient may develop acute and 
severe liver failure that is life-threatening in early infancy (<6 months of age). 
The survivors of the acute failure show before two years of life liver cirrhosis, 
complex renal tubulopathy, rickets, cardiomyopathy, and hemorrhagic syn-
drome. Hepatocellular carcinoma (HCC) is a frequent complication of this form 
of HT1, which is often the cause of death in early life in an untreated individual 
[22, 25, 31, 32].
2.3 Prevalence of HT-1
In general, hereditary tyrosinemia type-1 is a very rare inborn genetic disease 
affecting about one person in 100,000–120,000 live births worldwide [29, 31, 33, 
34]. In some areas, the incidence of HT1 is noticeably higher. In Norway, Finland, 
and Tunisia, the frequency of HT1 is 1:74,800, 1:60,000, and 1:14,804, respectively 
[35–37]. The highest prevalence of the disorder is observed in Canada (the Province 
of Quebec), which is about 1 in 16,000 live births [32, 33, 38, 39], and even in a 
certain region of Quebec near Saguenay-Lac Saint-Jean Jean, it is estimated to be 
1:1846 live births [32], and the carrier rate has been estimated to be between 1 in 20 
and 1 in 31 [39].
The estimated incidence of tyrosinemia in the Eastern Province of Saudi Arabia 
is 3 in 100,000 live births, although the authors concluded that data obtained from 
their study underestimate the true number [40].
Figure 2. 
Steps of tyrosine and its inborn enzymatic error of metabolism causing tyrosinemia type I, II, and III.
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2.4 Diagnosis
A diagnosis of HT-1 is made based upon thorough clinical evaluation, a detailed 
patient history, and specialized tests.
Elevated blood tyrosine level in newborns should be seen as soon as possible 
for clinical and laboratory evaluations for the possibility of HT-1. The diagnosis of 
HT-1 is based on elevated succinylacetone (SA) levels in the blood and or urine, as 
tyrosine elevation is an unreliable marker. There are many false-positive and false-
negative results when tyrosine is used as the only diagnostic parameter [41]. In the 
US, Canada, and some of the European countries, they use the detection of plasma 
SA as a newborn screening test for the detection of HT-1 [42].
If there is a high suspicion for HT-1, plasma amino acids (PAA) and liver func-
tion tests including prothrombin time (PT), international normalized ratio (INR), 
partial thromboplastin time (PTT), and α-fetoprotein (AFP) should be evaluated at 
the first visit. [43].
Clinical symptoms typically begin before two years of age, with the majority 
of children presenting before the age of 6 months with hepatosplenomegaly and 
evidence of acute liver failure and renal dysfunction. A few affected children may 
present over the age of 2 years with isolated coagulopathy or other signs of liver 
dysfunction, renal tubular disease, hypophosphatemic rickets, and failure to thrive. 
All children with HT-1 are at high risk for hepatocellular carcinoma (HCC), and this 
also may be the first recognized clinical event [44].
Molecular genetic testing for FAH gene mutations is available to confirm the 
diagnosis [45, 46].
2.5 Differential diagnosis
HT-1 should be differentiated from another inherited inborn autosomal reces-
sive disorders with dramatically elevated blood tyrosine levels such as:
Tyrosinemia type II, which is due to tyrosine aminotransferase (TAT) defi-
ciency as shown in Figure 2, causing accumulation of tyrosine that produces a 
severe dermatologic and ophthalmologic abnormalities. Type II tyrosinemia occurs 
in less than 1 in 250,000 individuals [47–49].
Tyrosinemia type III is due to 4-hydroxyphenylpyruvate dioxygenase (HPD) 
deficiency as shown in Figure 2. It is the rarest of the three conditions, with only 
a few cases ever reported. Most of those cases have included intellectual disability 
and neurologic dysfunction. It also has highly elevated blood tyrosine levels but 
does not manifest liver disease or renal tubular disease [50–53].
Tyrosinemia types II and III variably respond to phenylalanine and tyrosine 
dietary restriction therapies, unlike HT-I, the dietary restriction, even if begun 
within the first month of life, did not eliminate the development of hepatic, renal, 
or neurological complications.
Plasma amino acids (PAA) will help to differentiate tyrosinemia types II and III 
from HT-1 in those cases where the children are detected by an elevated tyrosine 
level but do not have detectable succinylacetone (SA).
2.6 Management of HT-1
2.6.1 Nitisinone drug therapy
Nitisinone, orfadin, or 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-
1,3-dione (NTBC). Its structure is shown in Figure 3.
5Successive Drug Therapy for a Very Rare Autosomal Diseases
DOI: http://dx.doi.org/10.5772/intechopen.89583
2.6.2 History of nitisinone discovery
Nitisinone is a member of the benzoylcyclohexane-1,3-dione family of herbi-
cides, which are chemically derived from a natural phytotoxin, leptospermone, 
obtained from the Australian bottlebrush plant (Callistemon citrinus) [29].
Nitisinone was discovered as part of a program to develop a class of herbicides 
called 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors. HPPD is essential 
in plants and animals for catabolism, or breaking apart, of tyrosine. In plants, 
preventing this process leads to the destruction of chlorophyll and the death of the 
plant [54].
In normal humans, fumarylacetoacetate hydrolase acts on the final step of 
tyrosine metabolism after HPPD does. The absence or weak activity of fumaryl-
acetoacetate hydrolase as in HT-1 leads to very harmful products building up in the 
body [24, 27–30]. So scientists working on making herbicides in the class of HPPD 
inhibitors hypothesized that inhibiting HPPD and controlling tyrosine in the diet 
could treat this disease. A series of small clinical trials attempted with one of their 
compounds, nitisinone, were conducted and were successful, leading to nitisinone 
brought to market as an orphan drug Swedish Orphan International, which was 
later acquired by Swedish Orphan Biovitrum (Sobi). [55, 56]. Therefore, in HT-1, 
the mechanism of nitisinone action will involve reversible inhibition of HPPD pre-
venting the formation of maleylacetoacetic acid and fumarylacetoacetic acid, which 
have the potential to be converted to succinylacetone, a toxin that damages the liver 
and kidneys. This causes the symptoms of HT-1 experienced by untreated patients.
Lock described nitisinone by a nice statement “From Weed Killer to Wonder 
Drug” [57].
2.6.3 The clinical trial of nitisinone
Sven Lindstedt recognized the potential value of NTBC for the treatment of 
HT-1. By blocking the proximal tyrosinemia pathway, NTBC minimizes the forma-
tion of FAA and maleylacetoacetic. It was this keen insight that led to the original 
clinical trial with five patients, which documented the rapid reversal of clinical 
symptoms [58].
NTBC dosing should be sufficient to completely suppress plasma and urine SA 
detection and normalize liver and renal function. SA, in either plasma or urine, 
should be below detectable limits (or within the limits of normal established by 
Figure 3. 
The structure of nitisinone (NTBC).
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the reference laboratory). The dose of NTBC should be increased if the SA level 
increases once patient adherence has been confirmed [43].
The standard recommended dosage of NTBC is 1 mg/kg body weight [43, 59, 60]. 
The half-life of NTBC has been measured in healthy human subjects and found 
to be approximately 54 h [61]. Because of this long half-life, a single daily dose of 
NTBC is satisfactory for maintaining inhibition of HPD [62, 63].
In the evaluation of its safety profile, rats and dogs exposed to NTBC developed 
elevated plasma tyrosine levels and ocular lesions. The ocular lesions (keratopathy) 
were caused by tyrosine crystals within the cornea, which on cessation of the diet 
recovered [43, 57].
The FDA approved NTBC in January 2002 [64].
2.6.4 Nutritional therapy
The combined nitisinone and low phenylalanine and tyrosine diet treatment 
should be initiated as soon as possible following the diagnosis of HT-1, to maintain 
PAA concentrations within the treatment range. Phenylalanine must be restricted 
in the diets of affected patients since approximately 75% of dietary phenylalanine 
is hydroxylated to form tyrosine [65, 66]. The combined diet restriction and NTBC 
treatment resulted in a greater than 90% survival rate, normal growth, improved 
liver function, prevention of cirrhosis, correction of renal tubular acidosis, and 
improvement in secondary rickets [67–69].
2.6.5 Liver transplantation
Before the availability of nitisinone for the treatment of tyrosinemia type I, the 
only definitive therapy was liver transplantation. The first case of HT-1 treated with 
liver transplant was in 1978 performed by Fisch and his colleagues [70]. The patient 
died 3 months later, but the biochemical derangements improved. Subsequently, 
the use of liver transplants in HRT cases has increased, and the benefits appear to be 
confirmed [71].
Liver transplantation should be reserved for those children who (1) have a severe 
liver failure at clinical presentation and fail to respond to nitisinone therapy or (2) 
have documented evidence of malignant changes in hepatic tissue [72]. Transplant 
recipients may also benefit from low-dose (0.1 mg/kg/day) nitisinone therapy to 
prevent continued renal tubular and glomerular dysfunction resulting from the 
persistence of succinylacetone in the plasma and urine [73].
2.6.6 Low phenylalanine and tyrosine diet restriction
Diet restriction for the treatment of HT-1 patients was introduced by Halvorsen 
and Gjessing in 1964 [19] and for a long time was the only treatment available. It 
had a beneficial effect on the renal tubular defects but did not cure the liver disease. 
A girl with HT-1, diagnosed at 6 months of age, was treated with a diet restricted in 
phenylalanine and tyrosine. At 9½ years of age, she developed an acutely enlarged 
liver and spleen, and the diagnosis of hepatocarcinoma was made [70].
2.6.7 Genetic therapy
Gene therapy is a promising means to cure many monogenic diseases. 
However, traditional gene therapies are best suited to treat diseases of deficient or 
absent gene products rather than those diseases caused by aberrantly functioning 
proteins [74].
7Successive Drug Therapy for a Very Rare Autosomal Diseases
DOI: http://dx.doi.org/10.5772/intechopen.89583
Adeno-associated virus (AAV)-mediated gene repair is feasible in vivo and can 
functionally correct a mouse model [74] and pig model of HT-1 [75] and con-
cluded that further exploration of ex vivo hepatocyte genetic correction is war-
ranted for clinical use. Although AAV-mediated gene therapy in a mouse model 
of HT-1 was successful as it has shown that none-treated FAH mutant control 
mice died within six weeks from fulminant liver failure, FAH adenovirus-infected 
animals survived 2–9 months. But this gene therapy does not obviate the tumor 
risk inherent in HT-1 as nine of 13 virus-treated animals developed hepatocellular 
cancer [76].
2.6.8 Family cases of HT-1 treated successively with nitisinone
We are reporting three Saudi siblings who have diagnosed as patients with HT-1. 
They are living in Najran city, the southern province of Saudi Arabia.
The first case is 27-year-old male patient. He has been diagnosed at the age of 
4 months in Great Ormond Street Hospital (London-UK) and treated by nitisinone 
in combination with tyrosine and phenylalanine-free diet. For the next 15 years, 
he used to visit the clinic for regular checking. The final report showed that he 
has good general health, with normal liver and renal function test and normal 
alpha-fetoprotein. Since then and until now, he attends the National Laboratory for 
Newborn Screening, Department of Genetics, King Faisal Specialist Hospital and 
Research Centre for a routine checkup. Still, he is on nitisinone and diet restriction. 
He has graduated from Najran Technical College, and now he is doing very well 
in his job as the vice director of staff affairs at Al-Ghad International College for 
Applied Medical Sciences in Najran-KSA.
The second case is his brother, who is 20 years old. He has been diagnosed in 
the first few days after birth by the National Laboratory for Newborn Screening, 
Department of Genetics, King Faisal Specialist Hospital and Research Centre, 
Riyadh, Saudi Arabia. Since then he has been treated by nitisinone in combination 
with tyrosine and phenylalanine-free diet. He is having good general and mental 
conditions. He is now a 2nd-year university student and doing well in his study.
The third case is their younger brother, who is 15 years old. Diagnosed since 
birth by the National Laboratory for Newborn Screening, Department of Genetics, 
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. Since 
then, he has also been put on nitisinone in combination with tyrosine and phenyl-
alanine-free diet. He is also having a good general and mental conditions. He is a 
secondary school student, and he is also doing very well in his study.
The three brothers are now on nitisinone in a dose of 1 mg/kg/day. It is marketed 
under the brand name Orfadin by the company Swedish Orphan Biovitrum (Sobi). 
Also, they are on tyrosine and a phenylalanine-free diet supplemented with HCU 
Anamix Junior LQ [Nutricia Advanced Medical Nutrition Company].
They have a regular visit to the National Laboratory for Newborn Screening, 
Department of Genetics, King Faisal Specialist Hospital, and Research Centre, 
Riyadh, Saudi Arabia for regular checking, and the last visit was a few weeks ago.
Their elder two siblings (sister and brother) died in their early life of unknown 
cause. The sister died at the age of 26 months. From the history of her mother, it 
seems that the daughter developed abdominal distension, and their doctors told 
her that the baby has hepatosplenomegaly. She also developed jaundice and became 
reluctant to milk or food. Until the day of death at the age of 26 months, she could 
not sit or walk; she was very week as her mother described.
Then after, they have a boy who developed after birth hepatomegaly, and 
jaundice, abdominal distension with very thin extremities and died early after birth 
at the age of 4 months, as his mother said.
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After the birth of the third baby (our first case), they went to Great Ormond 
Street Hospital and diagnosed as having tyrosinemia-1. At the same time, the 
parents diagnosed as a carrier of the disease.
The clinical history of their previous dead siblings suggested that they did have 
undiagnosed HT-1. Furthermore, the diagnosis of the parents that they are a carrier 
of the disease is highly supporting that the death of their two children early life was 
due to the lack of diagnosis and treatment of HT-1.
3. Discussion
HT-1 is a rare but clinically severe and fatal inborn error that principally affects 
the liver, kidney, and peripheral nerve [32]. In general, the most diagnosed patients 
of inborn errors of metabolism (IEMs) including HT-1, were born from consan-
guineous married parents. As HT-1 is a rare inherited autosomal recessive disorder, 
it explains why it is more common in population with a high rate of consanguineous 
marriages, such as in United Arab Emirates, Oman, Kuwait, and Saudi Arabia, 
in which the rate of consanguineous marriages reaches up to approximately 60% 
[33, 77–80], and even the first reported case of HT-1 in Japan (1957) was a child 
from parents of consanguineous marriage [13, 14]. Furthermore, in our study, the 
reported three family cases are also born from a consanguineous married parent.
In the sixties and early seventies HT-1 patients were treated by phenylalanine- 
and tyrosine-free died; it delayed the mortality and morbidity for a few years but 
it did not prevent the development of hepatic failure, renal complications and 
hepatocellular carcinoma (HCC) even if begun within the first month of life [43]. 
Then after, treatment with hepatic transplantation was the only option for survival. 
But it has been reported that the development of HCC was observed in 17–37% of 
affected children [81, 82]. Furthermore, after transplantation, urine and plasma 
SA decreases but is not completely suppressed [43, 63], and even other scientists 
reported that plasma succninylacetone is persistently raised after liver transplanta-
tion [73] presumably because of continued production in the kidneys which could 
cause damage to the liver and the kidney. Also, some of the patients died from 
the complications of hepatic transplant, whether the surgical or the immuno-
suppressive drug complications [43, 63, 69]. Therefore, in 1992, the introduction 
of nitisinone in combination with diet restriction was the ideal therapy for HT-1 
patients especially if started in their early neonatal days [58].
The three HT-1 patients in our study used nitisinone in combination with 
phenylalanine and tyrosine diet restriction from early days of their neonatal life and 
till now, which is 27, 20, and 15 years, respectively. They are not only still alive but 
also doing very well in their living.
These results justify implementing prevention programs that incorporate 
genetic counseling and neonatal diagnostic screening tests, especially in the sus-
pected families of consanguineous marriages to detect the neonatal patients with 
HT-1 as early as possible and then to start treatment which will minimize the lethal 
consequences of the disease.
All subsequent children of the parents of a child with HT-1 should have urine 
and blood succinylacetone analyzed as soon as possible after birth to enable the ear-
liest possible diagnosis and initiation of therapy. Early detection of newborn babies 
with HT-1, followed by prompt treatment with nitisinone in combination with a low 
phenylalanine and tyrosine diet has improved the survival to over 90% and resulted 
in normal growth, improved liver function, prevention of cirrhosis, correction of 
kidney disease, and improvement in rickets [41, 42, 83, 84]. In 2012, Larochelle 
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et al. reported that patients who receive nitisinone treatment before 1 month had no 
detectable liver disease after more than 5 years [69].
These data suggested that early neonatal diagnosis of HT-1 and treatment with 
nitisinone and diet restriction not only keep the survival of the patients but also 
keep them in good general, physical, and mental conditions.
4. Conclusion
Nitisinone (NTBC) has been used since 1992 and proves to be an effective and 
safe pharmacological treatment for HT-1 in combination with phenylalanine- and 
tyrosine-free diet.
In this paper, we are reporting three cases (brothers) treated safely and succes-
sively with NTBC in combination with diet. All of them are in very good condi-
tions. The elder brother is on NTBC since 27 years ago. He is one of the few cases 
worldwide treated since 1992 and till now, and he is living with a very good general 
health.
HT-1 is not only a rare and fatal autosomal disease, but it is a very rare genetic 
disease that can be successfully, effectively, and safely treated by drug therapy, 
which is nitisinone (NTBC).
4.1 Recommendation
We highly recommend establishing a national Newborn Screening Center, 
which provides newborn screening test for the diagnosis of HT-1, especially for the 
high-risk neonates in the suspected families. The use of tandem-mass-spectrometry 
could make an early diagnosis of HT-1 by measurement of succinylacetone in blood 
spot specimens.
Prenatal diagnosis is also possible by doing DNA analysis in addition to the 
detection of succinylacetone in the amniotic fluid of the suspected pregnancies.
Early diagnosis and treatment of this life-threatening disease provide an oppor-
tunity to intervene before symptom onset.
Furthermore, this report justifies implementing prevention program by doing 
genetic counseling and DNA analysis in the suspected families, where consanguine-
ous marriages are prevalent.
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